Comparative Pharmacology
Head-to-head clinical analysis: DEXILANT versus ESOMEPRAZOLE STRONTIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXILANT versus ESOMEPRAZOLE STRONTIUM.
DEXILANT vs ESOMEPRAZOLE STRONTIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexlansoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Proton pump inhibitor that inhibits the H+/K+ ATPase in gastric parietal cells, suppressing gastric acid secretion.
30 mg orally once daily for up to 8 weeks; for healing esophagitis, 60 mg orally once daily for up to 8 weeks; maintenance 30 mg orally once daily.
40 mg orally once daily; for healing of erosive esophagitis, 40 mg orally once daily for 4-8 weeks; for maintenance of healing of erosive esophagitis, 20 mg orally once daily; for GERD, 20 mg orally once daily; for Helicobacter pylori eradication, 40 mg orally twice daily for 10 days in combination with antibiotics.
None Documented
None Documented
Terminal elimination half-life is 1–2 hours in healthy subjects, but due to prolonged gastric acid suppression via irreversible binding to proton pumps, duration of action exceeds 24 hours. Half-life is not directly correlated with pharmacodynamic effect.
Terminal elimination half-life: 1.0–1.5 hours in healthy subjects; prolonged in poor CYP2C19 metabolizers (up to 3.5 hours).
Renal (approximately 50% as inactive metabolites) and fecal (approximately 50% as inactive metabolites).
Primarily hepatic metabolism via CYP2C19 and CYP3A4. Approximately 80% of metabolites are excreted in urine and 20% in feces via bile. Less than 1% excreted unchanged.
Category C
Category A/B
Proton Pump Inhibitor
Proton Pump Inhibitor